TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24841795
Drug: Ozanezumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanezumab treatment
Study: 23908486
Drug: Zoster vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster vaccine (ZV)
Study: 17682988
Drug: 15 infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 infusions of 1 mg/kg (group A)
Study: 17682988
Drug: 15 infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 infusions of 0.75 mg/kg (group B)
Study: 17682988
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of 1 mg/kg (group C)
Study: 17682988
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of 0.75 mg/kg (group D)
Study: 16287442
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL placebo
Study: 9446843
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of water (control)
Study: 9446843
Drug: 300 mL
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mL of table wine (28.4 g ethanol)
Study: 9446843
Drug: 750 mL
Normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mL of table wine (71 g ethanol)
Study: 67975
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered diamorphine every four hours at individually optimized doses in association with cocaine and a phenothiazine
Study: 67975
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered morphine every four hours at individually optimized doses in association with cocaine and a phenothiazine
Study: 25966305
Drug: Bicon(®) implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicon(®) implants (6 or 8 mm)
Study: 25966305
Drug: Ankylos(®) implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankylos(®) implants (8 mm)
Study: 22960769
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist started on day 1 of stimulation (Group 1)
Study: 22960769
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist started on day 5 of stimulation (Group 2)
Study: 20582874
Drug: GHRH injection
Normalized name: GHRH(1-44)
DrugBank: Somatorelin (DB12656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH injection (1 mu/kg body weight)
Study: 17019083
Drug: FX06 injection
Normalized name: FX06
DrugBank: FX06 (DB05685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX06 injection during and immediately after primary PCI
Study: 16061577
Drug: Outpatient family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient family therapy for 6 months
Study: 16061577
Drug: Outpatient family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient family therapy
Study: 12115176
Drug: CTLA‐4Ig (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTLA‐4Ig (0.5 mg/kg)
Study: 12115176
Drug: CTLA‐4Ig (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTLA‐4Ig (2 mg/kg)
Study: 12115176
Drug: CTLA‐4Ig (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTLA‐4Ig (10 mg/kg)
Study: 12115176
Drug: LEA29Y (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEA29Y (0.5 mg/kg)
Study: 12115176
Drug: LEA29Y (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEA29Y (2 mg/kg)
Study: 12115176
Drug: LEA29Y (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEA29Y (10 mg/kg)
Study: 10198864
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% drops (3 preoperative drops given 10 minutes apart)
Study: 7774989
Drug: lovastatin 40‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin 40‐80 mg once daily
Study: 26928727
Drug: Polypill (containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (containing aspirin, statin and two antihypertensives)
Study: 28341619
Drug: ERPonline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERPonline plus usual treatment
Study: 28341619
Drug: Waitlist (WL)
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Waitlist (WL) control plus usual treatment
Study: 22906798
Drug: Lithium monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium monotherapy (initial dose: 600mg/d, adjusted to therapeutic levels)
Study: 17150416
Drug: Monoimmunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoimmunotherapy with interferon‐alpha applied three times weekly for a total of 4 weeks
Study: 15520346
Drug: Vaccine offered
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine offered group
Study: 11281461
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (50 microgm, administered four hourly to a maximum of five doses)
Study: 11281461
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 microgm, administered four hourly to a maximum of five doses)
Study: 9771866
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg Ca/d as calcium citrate malate)
Study: 7787753
Drug: All transretinoic
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All transretinoic acid (ATRA) combined with intensive chemotherapy
Study: 2159696
Drug: 7.5 g
Normalized name: glucose 15 GM per 37.5 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g sodium propionate daily in capsule form
Study: 6784978
Drug: Naloxone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (20 mg infused over 3 h)
Study: 28892457
Drug: Romosozumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (210 mg monthly for 12 months)
Study: 23024190
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg weekly for 12 months)
Study: 20940517
Drug: C‐G‐A‐A‐A‐C‐C haplotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐G‐A‐A‐A‐C‐C haplotype
Study: 19217717
Drug: Orthopaedic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthopaedic manual therapy and exercise programme (OMTP)
Study: 2402207
Drug: Glycerol (1
Normalized name: GLYCEROL (1-(12-HYDROXYSTEARATE))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol (1 g.kg‐1 body weight) plus water (21.4 ml.kg‐1 body weight)
Study: 2402207
Drug: Water (21.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (21.4 ml.kg‐1)
Study: 2402207
Drug: Water (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (3.3 ml.kg‐1)
Study: 26100
Drug: Electropupillogram (E.P.G.)
Normalized name: E.S.P.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electropupillogram (E.P.G.) test dose of stimulant
Study: 28281731
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin
Study: 28237426
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy (GT) with a second subretinal injection in the contralateral eye
Study: 21803971
Drug: Intravenous hypotension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hypotension
Study: 16275807
Drug: Sarcosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcosine (2 g/d)
Study: 9456664
Drug: Orapette SalivaCard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orapette SalivaCard HIV‐1/HIV‐2 antibody test
Study: 7695268
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of piperacillin-tazobactam (50 mg/kg piperacillin and 6.25 mg/kg tazobactam)
Study: 7695268
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of piperacillin-tazobactam (100 mg/kg piperacillin and 12.5 mg/kg tazobactam)
Study: 7695268
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of piperacillin-tazobactam
Study: 29725975
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement (Familact®)
Study: 23897021
Drug: 1.25 g·d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 g·d of PEG‐creatine
Study: 23897021
Drug: 2.50 g·d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.50 g·d of PEG‐creatine
Study: 12499329
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lysine x kg(‐1) x d(‐1)
Study: 12499329
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg lysine x kg(‐1) x d(‐1)
Study: 12499329
Drug: 36 mg
Normalized name: pyrantel 136 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg lysine x kg(‐1) x d(‐1)
Study: 12499329
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg lysine x kg(‐1) x d(‐1)
Study: 12499329
Drug: 42 mg
Normalized name: lithium 42 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 mg lysine x kg(‐1) x d(‐1)
Study: 10660004
Drug: 60 mEq
Normalized name: phosphorus 45 MMOL / sodium 60 MEQ per 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mEq supplemental oral potassium daily
Study: 8646351
Drug: Intraperitoneal kanamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal kanamycin (500 mg)
Study: 6650492
Drug: DDAVP and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP and intravenous fluids
Study: 6650492
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and intravenous fluids
Study: 29422023
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy delivered by trained and supervised lay health workers (6 sessions)
Study: 19594194
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (SGAs) - olanzapine, quetiapine, risperidone, ziprasidone
Study: 19594194
Drug: First-generation antipsychotic
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotic (FGA) - perphenazine
Study: 19594194
Drug: First-generation antipsychotic
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotic (FGA) or second-generation antipsychotic (SGA) in CUtLASS
Study: 17475943
Drug: Prednisolone 60
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 60 mg on days 1 and 2, 40 mg on days 3 and 4, and 20 mg on days 5 and 6 (Group A)
Study: 17475943
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 6 days (Group B)
Study: 2694509
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of mefloquine/sulfadoxine/pyrimethamine (MSP)
Study: 30851699
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment for 9 weeks (specifics not provided)
Study: 25271009
Drug: Sucralose (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (24 mg in 200 ml of water)
Study: 25271009
Drug: Aspartame (72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (72 mg in 200 ml of water)
Study: 7647826
Drug: Water (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (200 ml)
Study: 23589672
Drug: Interleukin-7 (IL-7)
Normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-7 (IL-7) administered to virally suppressed subjects
Study: 19552904
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg, 3 times per day for 2 cycles)
Study: 17926620
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of 2000 microg of VitB12
Study: 17926620
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Carbamazepine
Study: 15529370
Drug: Alendronate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (40 mg daily)
Study: 11574913
Drug: 6-day dose
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-day dose escalation of TMP-SMZ
Study: 7836551
Drug: co‐trimoxazole 160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: co‐trimoxazole 160/800 mg twice a day
Study: 28380062
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1700 mL infused)
Study: 28380062
Drug: Gelatine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine 4% (1500 mL infused)
Study: 28380062
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) 6% (1500 mL infused)
Study: 28380062
Drug: Albumin 5%
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin 5% (1500 mL infused)
Study: 12743981
Drug: Pegylated-liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated-liposomal doxorubicin (Doxil™) at an initial dose of 55 mg/m2 every four weeks
Study: 8882073
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (250 micrograms) inhaled terbutaline
Study: 8882073
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (1000 micrograms) inhaled terbutaline
Study: 1348219
Drug: Formoterol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (4 x 6 micrograms twice a day and as necessary, n = 19)
Study: 1348219
Drug: Salbutamol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (4 x 100 micrograms twice a day and as necessary, n = 16)
Study: 3987793
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg 8 hourly
Study: 3987793
Drug: Nadolol 80
Normalized name: nadolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 80 mg with Nifedipine 20 mg
Study: 24725763
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with atorvastatin (20mg/day) and ezetimibe (10mg/day)
Study: 24725763
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with atorvastatin alone
Study: 20930431
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 mg/day) + alfacalcidol (0.25 µg/day)
Study: 20930431
Drug: Alfacalcidol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (0.25 µg/day) alone
Study: 15951474
Drug: Long-acting octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting octreotide 20 mg
Study: 15951474
Drug: Long-acting octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting octreotide 60 mg
Study: 15951474
Drug: Prolonged-release lanreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release lanreotide 90 mg
Study: 15951474
Drug: Prolonged-release lanreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release lanreotide 120 mg
Study: 10325895
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 micrograms twice daily plus the run in dose of fluticasone propionate
Study: 10325895
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the dose of fluticasone propionate (200 or 500 micrograms twice daily)
Study: 30819358
Drug: Prasugrel pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel pre-treatment
Study: 29077022
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g per day for six days)
Study: 31669625
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg/day)
Study: 24550580
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg/day) plus bromocriptine (0.8 mg/day)
Study: 24550580
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg/day) plus bromocriptine (1.6 mg/day)
Study: 22106246
Drug: High-volume fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume fluid therapy (10 mL/kg/h)
Study: 22106246
Drug: Low-volume fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume fluid therapy (4 mL/kg/h)
Study: 17704795
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care group (CC)
Study: 12499786
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 200mg IV q 12 hours for 3 days
Study: 7796076
Drug: Insulin Tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Tolerance Test (ITT)
Study: 31296300
Drug: On-treatment TIMI
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment TIMI major bleeding in patients with diabetes
Study: 27087507
Drug: Propiverine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine ER 30 mg
Study: 23351597
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (capsule) of levodropropizine 60 mg
Study: 23351597
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (syrup) of levodropropizine 60 mg
Study: 23351597
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (capsule and syrup)
Study: 11057790
Drug: Survanta (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survanta (100 mg/kg) - 0 doses
Study: 11057790
Drug: Survanta (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survanta (100 mg/kg) - 1 dose
Study: 11057790
Drug: Survanta (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survanta (100 mg/kg) - 2 doses
Study: 11057790
Drug: Survanta (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survanta (100 mg/kg) - 3 doses
Study: 11057790
Drug: Prenatal corticosteroid
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal corticosteroid treatment
Study: 2000045
Drug: methionyl recombinant
Normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: methionyl recombinant human growth hormone (met‐hGH) 0.06 IU/kg
Study: 6393665
Drug: Standardized therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized therapy
Study: 31490424
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg CAF + 100 mg CA
Study: 29310688
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day EPA/DHA
Study: 29310688
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day EPA/DHA
Study: 29310688
Drug: EPA/DHA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA/DHA therapy
Study: 22214903
Drug: Zolpidem (GABARα1-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (GABARα1-selective agonist)
Study: 15165934
Drug: losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 100 mg/day
Study: 20588058
Drug: candesartan 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: candesartan 12 mg/day
Study: 20588058
Drug: olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan 40 mg/day
Study: 22108775
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once daily
Study: 10594527
Drug: 0.3 mg/day
Normalized name: cloNIDine HCl 0.3 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/day conjugated equine oestrogens (CEE)
Study: 10594527
Drug: 0.6 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/day conjugated equine oestrogens (CEE)
Study: 10594527
Drug: 1.25 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/day conjugated equine oestrogens (CEE)
Study: 10594527
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of CEE
Study: 2085344
Drug: Acamprosate (CA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (CA), 1.3 g/day
Study: 28278602
Drug: CBT-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-only treatment (ACTION Treatment; Stark et al., 2006)
Study: 28666535
Drug: Childcare intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Childcare intervention alone (CC)
Study: 22030047
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg) followed by misoprostol (100 μg or 50 μg)
Study: 22030047
Drug: Misoprostol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (100 μg or 50 μg) alone
Study: 17453591
Drug: Structured interrupted
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured interrupted therapy (SIT)
Study: 29684092
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (CT)
Study: 12377961
Drug: No immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunotherapy (control)
Study: 9840563
Drug: Daily conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily conjugated equine estrogens
Study: 9840563
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens plus daily medroxyprogesterone acetate
Study: 7856287
Drug: Mumps vaccine,
Normalized name: mumps vaccine,live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mumps vaccine, strain Sofia 6